TSE:4507Pharmaceuticals
How Investors May Respond To Shionogi (TSE:4507) Acquiring Full RADICAVA Rights And Expanding In Rare Disease
Shionogi & Co., Ltd. has completed the acquisition of all rights to the ALS treatment RADICAVA (edaravone) from Tanabe Pharma, consolidating intellectual property and commercial control in major markets and expanding its rare disease portfolio.
This move effectively transforms Shionogi into a broader rare disease player by integrating RADICAVA’s commercial platform, infrastructure, and specialist teams into its global operations.
We’ll now examine how the RADICAVA rights transfer and...